| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 30 | 2021 | 492 | 4.300 |
Why?
|
| Brain Neoplasms | 27 | 2025 | 1216 | 2.940 |
Why?
|
| Polymorphism, Single Nucleotide | 40 | 2025 | 2637 | 2.210 |
Why?
|
| Genetic Predisposition to Disease | 31 | 2024 | 3157 | 2.030 |
Why?
|
| Genome-Wide Association Study | 15 | 2025 | 1689 | 1.260 |
Why?
|
| Lung Neoplasms | 12 | 2024 | 1659 | 1.240 |
Why?
|
| DNA Repair | 6 | 2021 | 585 | 0.950 |
Why?
|
| Glioblastoma | 8 | 2025 | 330 | 0.860 |
Why?
|
| Papillomavirus Infections | 2 | 2023 | 296 | 0.780 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2023 | 668 | 0.740 |
Why?
|
| Colon | 2 | 2025 | 351 | 0.730 |
Why?
|
| Neurocognitive Disorders | 1 | 2021 | 67 | 0.730 |
Why?
|
| DNA Ligases | 3 | 2010 | 17 | 0.710 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2023 | 165 | 0.700 |
Why?
|
| DNA-Binding Proteins | 8 | 2023 | 2048 | 0.670 |
Why?
|
| Head and Neck Neoplasms | 2 | 2023 | 503 | 0.670 |
Why?
|
| Germ-Line Mutation | 4 | 2016 | 333 | 0.650 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2010 | 131 | 0.630 |
Why?
|
| Polymorphism, Genetic | 5 | 2021 | 816 | 0.620 |
Why?
|
| Intestinal Mucosa | 2 | 2025 | 778 | 0.610 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 348 | 0.540 |
Why?
|
| Bacteria | 2 | 2025 | 484 | 0.540 |
Why?
|
| Diet | 2 | 2025 | 1140 | 0.540 |
Why?
|
| Liver Cirrhosis | 4 | 2024 | 832 | 0.540 |
Why?
|
| DNA Helicases | 4 | 2011 | 231 | 0.520 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2025 | 702 | 0.520 |
Why?
|
| Middle Aged | 40 | 2025 | 26927 | 0.520 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2010 | 197 | 0.500 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 33 | 0.500 |
Why?
|
| Genetic Variation | 4 | 2018 | 1502 | 0.490 |
Why?
|
| Chromosome Mapping | 4 | 2013 | 1078 | 0.480 |
Why?
|
| Haplotypes | 10 | 2012 | 522 | 0.450 |
Why?
|
| Adult | 35 | 2025 | 29628 | 0.450 |
Why?
|
| Hepatitis C, Chronic | 2 | 2018 | 327 | 0.440 |
Why?
|
| Genotype | 17 | 2017 | 2565 | 0.400 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 191 | 0.400 |
Why?
|
| Exome | 3 | 2016 | 1034 | 0.400 |
Why?
|
| Aged | 22 | 2025 | 19870 | 0.400 |
Why?
|
| Hepacivirus | 1 | 2013 | 244 | 0.380 |
Why?
|
| Veterans | 2 | 2023 | 1748 | 0.380 |
Why?
|
| Case-Control Studies | 19 | 2023 | 3299 | 0.380 |
Why?
|
| Humans | 64 | 2025 | 125189 | 0.380 |
Why?
|
| Male | 47 | 2025 | 61525 | 0.370 |
Why?
|
| Risk Factors | 20 | 2024 | 10315 | 0.370 |
Why?
|
| DNA Copy Number Variations | 2 | 2013 | 949 | 0.360 |
Why?
|
| Cognition Disorders | 1 | 2015 | 550 | 0.350 |
Why?
|
| Female | 47 | 2025 | 66806 | 0.350 |
Why?
|
| Gamma Rays | 1 | 2010 | 50 | 0.340 |
Why?
|
| HMGA2 Protein | 1 | 2010 | 11 | 0.340 |
Why?
|
| Genetic Linkage | 3 | 2018 | 453 | 0.330 |
Why?
|
| Inflammation | 5 | 2018 | 1446 | 0.320 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 1496 | 0.320 |
Why?
|
| Breast Neoplasms | 4 | 2014 | 2513 | 0.320 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 426 | 0.310 |
Why?
|
| Survivors | 1 | 2010 | 339 | 0.280 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2024 | 930 | 0.280 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 351 | 0.280 |
Why?
|
| Molecular Epidemiology | 2 | 2018 | 155 | 0.280 |
Why?
|
| Telomerase | 2 | 2021 | 160 | 0.260 |
Why?
|
| Pedigree | 8 | 2018 | 1606 | 0.260 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 1314 | 0.250 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2025 | 367 | 0.240 |
Why?
|
| DNA Ligase ATP | 3 | 2010 | 11 | 0.240 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 919 | 0.240 |
Why?
|
| ErbB Receptors | 3 | 2011 | 281 | 0.230 |
Why?
|
| Dairy Products | 1 | 2025 | 45 | 0.230 |
Why?
|
| Carrier Proteins | 1 | 2010 | 1022 | 0.230 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 468 | 0.230 |
Why?
|
| Smoking | 6 | 2024 | 1051 | 0.230 |
Why?
|
| Phospholipases A2, Calcium-Independent | 1 | 2024 | 13 | 0.220 |
Why?
|
| Mouth Diseases | 1 | 2023 | 12 | 0.210 |
Why?
|
| Immunogenetics | 1 | 2023 | 8 | 0.210 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2023 | 23 | 0.210 |
Why?
|
| Neoplasm Grading | 5 | 2017 | 272 | 0.200 |
Why?
|
| Prognosis | 6 | 2025 | 4645 | 0.200 |
Why?
|
| Linkage Disequilibrium | 7 | 2013 | 309 | 0.200 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 346 | 0.190 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 326 | 0.180 |
Why?
|
| Young Adult | 13 | 2025 | 9053 | 0.180 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 3425 | 0.180 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 1275 | 0.180 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 604 | 0.170 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1360 | 0.170 |
Why?
|
| Thrombosis | 1 | 2025 | 526 | 0.170 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5176 | 0.160 |
Why?
|
| Alleles | 7 | 2017 | 1614 | 0.160 |
Why?
|
| Gene Frequency | 5 | 2015 | 724 | 0.160 |
Why?
|
| Microbiota | 1 | 2023 | 389 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2023 | 1893 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1324 | 0.140 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 478 | 0.140 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 122 | 0.140 |
Why?
|
| Models, Genetic | 2 | 2012 | 760 | 0.140 |
Why?
|
| Odds Ratio | 5 | 2015 | 1259 | 0.140 |
Why?
|
| Risk | 4 | 2017 | 756 | 0.140 |
Why?
|
| Mexican Americans | 1 | 2018 | 202 | 0.140 |
Why?
|
| Myeloid Cells | 1 | 2017 | 102 | 0.140 |
Why?
|
| Genetic Association Studies | 6 | 2018 | 779 | 0.130 |
Why?
|
| China | 7 | 2011 | 246 | 0.130 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 281 | 0.130 |
Why?
|
| Drug Design | 1 | 2017 | 152 | 0.130 |
Why?
|
| Hypertension | 1 | 2025 | 1330 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6598 | 0.130 |
Why?
|
| Carcinoma, Large Cell | 1 | 2016 | 9 | 0.130 |
Why?
|
| Recombinational DNA Repair | 1 | 2015 | 16 | 0.120 |
Why?
|
| Risk Assessment | 5 | 2024 | 3465 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 45 | 0.120 |
Why?
|
| Family Health | 2 | 2013 | 259 | 0.120 |
Why?
|
| Computational Biology | 1 | 2019 | 810 | 0.110 |
Why?
|
| Telomere-Binding Proteins | 1 | 2014 | 43 | 0.110 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2014 | 39 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 319 | 0.110 |
Why?
|
| Proteomics | 1 | 2017 | 502 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2015 | 369 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2013 | 78 | 0.100 |
Why?
|
| Penetrance | 1 | 2013 | 102 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2016 | 4817 | 0.100 |
Why?
|
| Obesity | 1 | 2024 | 2248 | 0.100 |
Why?
|
| Mutation | 3 | 2021 | 5845 | 0.100 |
Why?
|
| Age Factors | 3 | 2021 | 2823 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 356 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 1056 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 723 | 0.100 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2011 | 11 | 0.100 |
Why?
|
| Family | 1 | 2015 | 566 | 0.090 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 50 | 0.090 |
Why?
|
| Adolescent | 9 | 2018 | 19363 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 248 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 71 | 0.090 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2009 | 63 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 686 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 73 | 0.090 |
Why?
|
| Antigens, Nuclear | 1 | 2011 | 60 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2011 | 230 | 0.090 |
Why?
|
| Decision Trees | 1 | 2010 | 50 | 0.080 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 123 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 2891 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 189 | 0.080 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2009 | 21 | 0.080 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2009 | 12 | 0.080 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 23 | 0.080 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 39 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 44 | 0.080 |
Why?
|
| Endonucleases | 1 | 2009 | 54 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 61 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 589 | 0.080 |
Why?
|
| Quantitative Trait Loci | 2 | 2022 | 287 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2024 | 6153 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 412 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 1026 | 0.070 |
Why?
|
| Astrocytoma | 1 | 2009 | 100 | 0.070 |
Why?
|
| One-Carbon Group Transferases | 1 | 2008 | 1 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 558 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2010 | 185 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 618 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2025 | 603 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2008 | 88 | 0.070 |
Why?
|
| Pyrenes | 1 | 2007 | 5 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2009 | 781 | 0.070 |
Why?
|
| Mutagens | 1 | 2007 | 84 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 515 | 0.070 |
Why?
|
| Melanoma | 1 | 2014 | 942 | 0.070 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2007 | 67 | 0.060 |
Why?
|
| Phenotype | 1 | 2016 | 4262 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 2007 | 128 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2015 | 4534 | 0.060 |
Why?
|
| Mass Screening | 1 | 2011 | 784 | 0.060 |
Why?
|
| Cheese | 1 | 2025 | 8 | 0.060 |
Why?
|
| Yogurt | 1 | 2025 | 13 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 335 | 0.060 |
Why?
|
| Lung | 2 | 2023 | 1496 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 1112 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2025 | 64 | 0.060 |
Why?
|
| Genome, Human | 1 | 2011 | 1272 | 0.060 |
Why?
|
| Survival Rate | 2 | 2025 | 2062 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2024 | 44 | 0.060 |
Why?
|
| Smokers | 1 | 2024 | 39 | 0.050 |
Why?
|
| Logistic Models | 1 | 2009 | 1810 | 0.050 |
Why?
|
| Lipase | 1 | 2024 | 93 | 0.050 |
Why?
|
| DNA Damage | 1 | 2007 | 513 | 0.050 |
Why?
|
| United States | 5 | 2024 | 10915 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2023 | 144 | 0.050 |
Why?
|
| Asthma | 1 | 2010 | 756 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2014 | 101 | 0.050 |
Why?
|
| Lod Score | 2 | 2012 | 120 | 0.050 |
Why?
|
| Sweden | 2 | 2013 | 34 | 0.050 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2021 | 20 | 0.050 |
Why?
|
| Denmark | 2 | 2013 | 33 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 108 | 0.050 |
Why?
|
| Research Design | 1 | 2024 | 695 | 0.040 |
Why?
|
| Time Factors | 1 | 2010 | 6338 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 482 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 557 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 1755 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2008 | 2593 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 573 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 141 | 0.040 |
Why?
|
| Child | 4 | 2013 | 24421 | 0.030 |
Why?
|
| Data Mining | 1 | 2017 | 53 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2024 | 1527 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 794 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2018 | 359 | 0.030 |
Why?
|
| Prevalence | 2 | 2013 | 2458 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 517 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 96 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 22 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 15 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2014 | 53 | 0.030 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2014 | 36 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2010 | 12392 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 657 | 0.030 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2013 | 4 | 0.030 |
Why?
|
| RNA 3' End Processing | 1 | 2013 | 6 | 0.030 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2013 | 13 | 0.030 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2013 | 9 | 0.030 |
Why?
|
| Israel | 1 | 2013 | 46 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2013 | 140 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2013 | 97 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2012 | 114 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 354 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2011 | 8 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 2011 | 24 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2011 | 21 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2011 | 125 | 0.020 |
Why?
|
| Homozygote | 1 | 2013 | 547 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 85 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 595 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2011 | 128 | 0.020 |
Why?
|
| Finland | 1 | 2010 | 42 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2011 | 93 | 0.020 |
Why?
|
| England | 1 | 2010 | 59 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 553 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 3103 | 0.020 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2011 | 74 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2913 | 0.020 |
Why?
|
| Eczema | 1 | 2010 | 29 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 875 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3892 | 0.020 |
Why?
|
| Neuroimmunomodulation | 1 | 2009 | 15 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2021 | 16353 | 0.020 |
Why?
|
| Metabolism | 1 | 2009 | 42 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1438 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2011 | 339 | 0.020 |
Why?
|
| Carcinoma | 1 | 2011 | 287 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 897 | 0.020 |
Why?
|
| Biomarkers | 2 | 2009 | 3091 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1289 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 789 | 0.020 |
Why?
|
| Meningioma | 1 | 2009 | 120 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 184 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 362 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2014 | 14027 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 399 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 25 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 1016 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1140 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2007 | 68 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 617 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 155 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1586 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 3147 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2008 | 471 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 389 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 1288 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1460 | 0.010 |
Why?
|
| Animals | 1 | 2025 | 34232 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 12516 | 0.010 |
Why?
|